VIDA focuses on accelerating respiratory clinical trials through data-driven clinical trial methodologies, including optimized imaging operations and data insights.

VIDA

VIDA | 5,381 followers on LinkedIn. Modernizing Lung and Respiratory Care | VIDA is a clinical imaging intelligence company that is accelerating the approval and adoption of life-saving therapies to patients through an AI-powered digital biomarker solution. With proprietary imaging biomarkers for precise quantitative endpoints and a trial imaging management solution, VIDA’s solution is helping biopharma sponsors save millions in drug development costs.

Corporate Board Director, ResMed, Outset Medical … Former CEO

Karen Drexler

Sandra Stapleton

Marketing at VIDA Diagnostics

Marcel Nienhuis

Director of Human Resources at VIDA

Shanna Lynnes

We are honored to welcome Wisia Wedzicha, MD, PhD, an expert in COPD, as our next webinar guest! Dr. Wedzicha will dive into BEACON, a unique study uncovering the earliest signs of COPD in young smokers with normal spirometry 🫁. The BEACON study was featured on the cover of the Blue Journal (AJRCCM) 📖 earlier this year. 👉 Save your spot now: https://lnkd.in/gNu9b8Rm #COPD #BEACON #VIDAPresents #Webinar

New findings from Brightling et al. on the relationship between mucus plugging and air trapping: "A reduction in mucus plugging with tezepelumab treatment was correlated with a spatially-associated improvement in air trapping index." https://hubs.la/Q02YxKQ50 Authors: chris brightling , Å Hellqvist, S Diver, C Porsbjerg, E Israel, John D Newell , Sam Peterson , JM Sepena, AW Lindsley, A Megally, Lars Haug Nordenmark British Thoracic Society (BTS)

For our US employees, today is the day #VIDAVotes ! 🇺🇸 All employees are granted a 4-hour window today, ensuring ample time to exercise our right to vote. See you at the polls! #gotv #vote #voting #electionday #teamVIDA

An excellent editorial by Cara Flynn and Chris Brightling: "Picture this: the future of imaging biomarkers in COPD." https://hubs.la/Q02W3MPq0 "In the near future, artificial intelligence, which is advancing rapidly in other areas of imaging, could be more widely adopted forCOPD imaging."

November is #Alpha1Awareness Month! Join us in raising awareness for Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can lead to serious lung and liver diseases. We are committed to help accelerate new therapies to these patients. ICYMI, here's our webinar with Dr. Barjaktarevic on the topic. https://hubs.la/Q02Wy3vZ0 #AATD

Happy Halloween 🎃 from VIDA! May your evening be full of treats. 👻 🕸️🕷️ #HappyHalloween #TeamVIDA

Can CT help find 🕵🏽♂️ those elusive PRISm* patients? Lukhumaidze and colleagues just shared some promising results that point to "yes." They examined a wide range of quantitative imaging biomarkers and found "reduced lung volumes, elevated HAA%, and elevated GGO/reticulation patterns are associated with stable PRISm." More here: https://hubs.la/Q02W7Xtt0 Authors: Leila Lukhumaidze, MSc, James C. Hogg, MD, PhD, Jean Bourbeau, MD, Wan C. Tan, MD, Miranda Kirby, PhD *PRISm stands for "Preserved Ratio Impaired Spirometry." It occurs when a person has a simultaneous reduction in both FEV1 and FVC, resulting in a preserved FEV1/FVC ratio of 0.70 or higher (thereby not meeting a common diagnostic criteria for COPD, despite compromised lung function). #PRISm #COPD #digitalbiomarkers #QCT #HAA #LAA #TLV #GGO

New research on vascular chest CT biomarkers from the #CanCOLD group: "Resting pulmonary vascular volumes (TVV) and DLCO were associated with Vo2peak. These results suggest that the association of pulmonary vascular structure/function with Vo2peak may be important across the continuum of health and disease." Authors: Sophie É. Collins, PhD, Miranda Kirby , PhD, Benjamin M. Smith, MD, FRCPC, Wan Tan, MD, Jean Bourbeau, MD , Stephanie Thompson, MD, PhD, Sean van Diepen, MD, Dennis Jensen, PhD, Sanja Stanojevic, PhD, Michael Stickland, PhD #COPD #TVV #BV5 #BV10 #DigitalBiomarkers American College of Chest Physicians https://hubs.la/Q02W06Yx0

ICYMI, Rachel Eddy , PhD recently appeared on the American Lung Association 's Lungcast podcast. She gives an excellent overview of AI applications in quantitative lung imaging, including airway remodeling biomarkers, fibrosis scoring, mucus analysis, dysanapsis, xenon MRI, micro CT and more. Check it out here: https://hubs.la/Q02SpW3j0 #AI #XenonMRI #digitalbiomarkers #asthma #ILD #COPD #mucus #microCT #fibrosis #QCT

Going to #CHEST24 this week? Be sure to check out the poster from Stalker, G. et al. on air trapping and GGO in acute COVID as a predictor for Long COVID. The presentation is Oct 8 1:45p-2:30p. https://hubs.la/Q02R151s0 By the way, we spoke with Dr. Comellas about the utility of quantitative imaging in Long COVID. Highlights of that conversation: https://hubs.la/Q02R1jNR0 #CHEST2024 #AirTrapping #vDPM #COVID #LongCOVID

Viewport Meta

IPhone / Mobile Compatible

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Analytics

DNSSEC

WordPress

Amazon

Global Site Tag

Founder

Joe Reinhardt

Vice President of Marketing

VP Commercial Operations

Margaret Cranston

Director, Customer Success & IT

Andrei V.

Engineering

Benj Thomas

Director of Product Management

Clive Wingar

Consulting

DeGuerre Blackburn

Vice President, Business & Clinical Development at VIDA

Joseph Reif

Director Clinical Development

Joshua Schirm

Director of Engineering

Juerg Tschirren

Bruce Luehrs

Craig Ibsen

Matthew Warrens

Susan A. Wood

President & Chief Executive Officer

Chief Operations Officer

Nate Dalton

Director

Vice President, Sales & Commercial Operations

Joseph M. Reinhardt

Eric A. Hoffman

Co-Founder

Kelly Thotland

Product Marketing Manager

United States Health Care Companies (Top 10K)

Health Diagnostics Companies With More Than 10 Employees (Top 10K)

Biotechnology Companies With Fewer Than 100 Employees (Top 10K)

Medical Companies With Fewer Than 1000 Employees (Top 10K)

VIDA modernizes lung and respiratory care, empowering healthcare organizations and physicians to improve patient outcomes, streamline care coordination and drive efficiencies through a comprehensive approach, proven quality, and clinical leadership. Through quantitative data intelligence and impactful visualizations, VIDA helps physicians manage patients with or at risk of chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), lung cancer, and now, COVID-19. VIDA’s software is FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, European Economic Area, Canada, and Australia. Learn more at vidalung.ai.

Venture Round - VIDA

OSF Ventures

Series C - VIDA

First Analysis

UnityPoint Health Ventures

Corporate Round - VIDA

Iowa Innovation Acceleration Fund

Debt Financing - VIDA

Chartline

Series B - VIDA

Next Level Ventures

Seed Round - VIDA

Computer and Software Products and Electrical and Scientific Products

Coralville

Iowa

United States

North America

'Vida' to End With Season 3 on Starz

VIDA Diagnostics Gains Distribution With EnvoyAI To Make AI Lung Imaging More Widely Available

VIDA Strengthens its Solution for Endobronchial Lung Volume Reduction (ELVR) Planning with Notice of Allowance for New Patent and Release of VIDA|vision® 2.1

news impact assignment basic	general
public peers	general	Nov 22, 2024 7:37 AM	02410d9a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 22, 2024 7:37 AM	c4b4869a
crunchbase trigger	general	Nov 22, 2024 7:37 AM	be7b38d4
crunchbase profile	general	Nov 23, 2024 5:54 AM	f61d165e
li profile	general	Nov 22, 2024 7:37 AM	7edc39b1
translate crunchbase fundingrounds	general	Nov 23, 2024 6:27 AM	823918b1
peers	general	Nov 22, 2024 7:37 AM	95d028f5
news basic	general	Nov 22, 2024 7:37 AM	9febbd68
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

VIDA

AI:VIDALUNG

VIDA